Quantification of the impact of Gadolinium agent on amide-proton-transfer weighted MRI: an ex vivo and in vivo study
Qian Yang1, Zhou Liu1, Yin Wu2, Long Qian3, and Dehong Luo1
1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China, 2Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China, 3MR Research, GE Healthcare, Beijing, China
The clinical value of Amide proton transfer (APT) imaging in brain tumors has been intensively studied and validated. However, whether and how much Gadolinium-based (Gd) agent in clinical dosage has impact on the APT-weighted signal in clinical scenarios remains controversial. Hence, this study designed an in vitro study using a phantom with a gradient dosage of Gd-based agent and then validated the result in 6 patients with brain tumors. The result revealed that APT effect was significantly influenced by Gd contrast agent both in the phantom in vitro study and in vivo study.
This abstract and the presentation materials are available to members only;
a login is required.